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progression of MM is associated with osteolytic lesions, bone 
marrow failure, suppression of normal Ig production and renal 
insufficiency.
Multiple myeloma is characterized by various cytogenetic abnor-
malities some of which are of prognostic significance (Fonseca 
et al., 2004; Avet-Loiseau et al., 2007). Specifically, del(13), t(11;14), 
t(4;14), t(14;16), hyperdiploidy, MYC translocations, and del(17p) 
are among the most common cytogenetic changes in MM patients. 
Univariate statistical analyses revealed that del(13), t(4;14), non-
hyperdiploidy, and del(17p) negatively impact both the event-free 
survival and the overall survival, whereas t(11;14) and MYC trans-
locations are thought not to influence the prognosis. Nevertheless, 
cumulative evidence suggest that only t(4;14) and del(17p) retained 
prognostic value for both the event-free and overall survivals as 
assessed by multivariate analyses (Avet-Loiseau et al., 2007; Neben 
et al., 2010). These results have implications for risk-adapted 
management for patients with MM and may suggest that differ-
ent treatment options might have variable success, depending on 
the underlying genetic nature of the clone. Despite these recent 
advances in cytogenetics, oncogenomics, and MM cell–stroma 
interactions (Avet-Loiseau et al., 2007; Katz, 2010; Neben et al., 
2010; Anderson, 2011), further studies are required to better reveal 
critical players in MM development. The emerging role of micro-
RNAs (miRNAs) in numerous types of human cancer led us and 
others to hypothesize that this group of non-coding genes might 
also be involved in the pathogenesis of MM.
MicroRNAs are a relatively recently identified class of regula-
tory non-coding RNAs, typically 19–25 nucleotides in length, that 
function primarily by targeting specific messenger RNAs (mRNAs) 
IntroductIon
Multiple myeloma (MM) is a clonal B-cell malignancy charac-
terized by the aberrant expansion of plasma cells (PCs) within 
the bone marrow, as well as into extramedullary sites (Bommert 
et al., 2006; Mahindra et al., 2010). The American Cancer Society 
estimates that 20,180 new cases of MM (11,170 in men and 9,010 
in women) will be diagnosed while 10,650 deaths are expected to 
occur in the United States in 2010 (A.C.S., 2010). The lifetime risk 
of getting MM is 1 in 159 (0.63%) and the 5-year relative survival 
rate for MM is around 35%. Although the exact causes of MM 
remain elusive, our understanding of the cellular events underlying 
MM development is greatly advancing. This has been facilitated by 
extensive research that enabled thorough analysis of the changes 
during the pathogenesis of MM.
Multiple myeloma develops from a benign condition called 
monoclonal gammopathy of undetermined significance 
(MGUS) (Weiss et al., 2009). Individuals with MGUS often 
remain stable for years and do not require treatment. However, 
for unknown reasons, this benign condition can evolve into MM 
at a rate of ∼1% per year, with some MMs developing after 
many years (Kuehl and Bergsagel, 2002; Fonseca et al., 2009). 
Malignant PCs progressively infiltrate the bone marrow and 
produce monoclonal immunoglobulin (Ig) (M protein) or an 
Ig chain (M-component). It is well known that the bone mar-
row microenvironment plays a prominent role in the biology of 
MM; adhesion of MM cells to the bone marrow stroma triggers 
cytokine production, enhances cell proliferation and resistance 
to chemotherapy by activation of NFκB, PI3K/AKT, and STAT-3 
pathways through IL-6 (Kastrinakis et al., 2000; Katz, 2010). The 
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doi: 10.3389/fgene.2011.00022for   degradation or inhibition of translation through base pairing to 
partially or fully complementary sites (Ambros, 2003; Bartel, 2004). 
MiRNAs are involved in a variety of biological processes, including 
development, differentiation, apoptosis, survival, senescence, and 
metabolism (Ambros, 2004; He and Hannon, 2004). Several hundred 
miRNAs have been identified and studied so far, but it is predicted 
that there are many more miRNAs whose significance and role in 
homeostasis and pathology is yet to be identified. In 2002, miR-15a 
and miR-16-1 located at 13q14.3, a region that is commonly deleted 
in chronic lymphocytic leukemia (CLL) and MM, were identified 
as potential cancer genes in the pathogenesis of CLL (Calin et al., 
2002). This finding provided the first evidence that miRNA genes 
might be important for cancer development. Later on, the use of dif-
ferent approaches including microarrays (Calin et al., 2004; Volinia 
et al., 2006) and quantitative reverse transcription PCR (qRT-PCR; 
Schmittgen et al., 2004; Jiang et al., 2005), revealed that miRNAs 
are differentially expressed in cancer cells and identified significant 
miRNA genes that are of biological and clinical relevance in human 
diseases (Volinia et al., 2006; Liu et al., 2008). Several miRNAs have 
been identified as oncomirs (miRNAs that are amplified or overex-
pressed in cancer and were shown to have a promoting role in the 
development of primary tumors) or tumor suppressors (miRNAs that 
are deleted or reduced in cancer cells and their loss is associated with 
tumor development; reviewed in Calin and Croce, 2006; Ventura and 
Jacks, 2009). Various causes of deregulated miRNA expression in can-
cer have been identified including changes in gene copy number (CN), 
chromosomal translocation, mutations, transcriptional activation, 
epigenetic silencing and defective miRNA processing, and biogenesis 
(Calin and Croce, 2006). Collectively, it is realized that deregulation 
of, at least some, miRNAs might also contribute to tumorigenesis.
During the last 4 years, several studies investigated miRNAs 
expression and function in the pathogenesis of MM. In this review, 
we will discuss the classification of these miRNAs, their cause of 
deregulation, the mechanisms by which these genes exert their func-
tions and the clinical relevance of their expression in MM.
MirnAs Are dIfferentIAlly expressed In MM
Initially, it has been shown that miR-21 levels in MM cells are con-
trolled in a STAT-3-IL-6 dependent manner (Loffler et al., 2007). 
Treatment of IL-6-dependent MM cells with IL-6 activated STAT-
3, which in turn enhanced miR-21 transcription. Importantly, 
ectopic expression of miR-21 was sufficient to sustain growth of 
IL-6-dependent MM cells in the absence of IL-6. Subsequent stud-
ies showed that miR-21 levels are upregulated in MM and MGUS 
samples with respect to its levels in healthy PCs (Pichiorri et al., 
2008; Zhou et al., 2010, see below). These results suggested that 
miRNAs levels might be implicated in MM pathogenesis.
In 2008, we reported a unique and comprehensive miRNA 
expression profiling of normal PCs, MGUS, and MM (Pichiorri 
et al., 2008). We utilized both a custom-made microarray chip and 
qRT-PCR of CD138+ normal PCs, MGUS, primary samples and 
MM cell lines. When compared with normal PCs, MGUS patients 
revealed a group of upregulated miRNAs with known oncogenic 
potential including miR-21 and the miR-106∼25 cluster. Although 
we are aware that the small set of MGUS samples (n = 10) used 
for these analyses could limit its significance, our study for the 
first time suggested that miRNAs deregulation could be associated 
with early stages of PC transformation. The fact that both miR-21 
and the miR-106∼25 cluster were shown to target, among others, 
PTEN, BIM, and p21, tumor suppressors that inhibit survival and 
promote apoptosis, could suggest that these miRNAs predispose to 
secondary events that might ultimately lead to full blown myeloma.
To better shed light on the role of miRNAs in MM, we next 
analyzed their expression in a group of MM cell lines and normal 
PCs (Pichiorri et al., 2008). Our data revealed a signature comprised 
of upregulated miRNAs, including among others miR-32, miR-21, 
miR-17∼92, miR-106∼25, and miR-181a/b. The Myc related miR-
17∼92 cluster were highly expressed only in MM patients, suggest-
ing that these miRNAs are MM-specific and their expression could 
be related to Myc upregulation during MM progression (Chesi 
et al., 2008). To further investigate the potential involvement of 
miRNAs in MM, Zhou et al. (2010) performed integrative analy-
ses of both miRNA expression profiles and protein coding gene 
expression profiles of myeloma cells. Their analyses reveal a global 
increase in miRNA expression in high-risk (poor prognosis) MM 
patients. This association was reinforced by the increase in viability 
of MM cells depleted of Argonaute 2 (AGO2), a master regulator 
of miRNA maturation and function (Liu et al., 2004; Diederichs 
and Haber, 2007). In fact, AGO2 is also involved in B-cell differ-
entiation (O’carroll et al., 2007) and was reported as an impor-
tant marker for MM disease prognosis (Shaughnessy et al., 2007). 
Nevertheless, expression of AGO2 did not significantly associate 
with global miRNA (Zhou et al., 2010) suggesting that other factors 
might contribute to the overall deregulation of miRNA in MM. 
Analysis of miRNA expression by another group revealed upregu-
lation of miR-193b-365 among previously identified oncomiRs 
(Unno et al., 2009).
Intriguingly, many of the aforementioned miRNAs were previ-
ously identified (Pichiorri et al., 2008), though others were not 
or had an opposite trend. These differences could stem from the 
different platforms used for analyzing miRNA expression, number 
of cases analyzed and/or genetic and cytogenetic abnormalities 
in the different cases or cell lines. Furthermore, it is possible that 
miRNAs play opposing roles at different stages of the disease; i.e., 
in MGUS versus MM. Regardless of the disagreement among the 
different studies, the overall conclusions confirm that deregulation 
of miRNA expression adds a further level to our understanding of 
the biological and clinical variability of MM and warrants further 
investigations.
MechAnIsMs of mirnA deregulAtIon In MM
Additional studies further demonstrated deregulation of miRNA 
expression in the different subtypes of MM and shed light on the 
mechanism of this alteration. Lionetti et al. employed an integra-
tive high-resolution microarray analysis of miRNAs and DNA CN 
or gene expression profiles in MM cell lines (Lionetti et al., 2009). 
These analyses revealed the deregulation of 16 miRNAs mapped to 
chromosomal regions frequently involved in allelic imbalances in 
MM. Among these were miR-22 at 17p13.3, miR-106b and miR-25 
at 7q22.1, miR-15a at 13q14.3, miR-21 at 17q23.1, and miR-92b 
at 1q22. In another study, it was shown that expression of miR-
15a/16-1 cluster at 13q14 display a range of expression patterns in 
MM cases independent of chromosome 13 status (Roccaro et al., 
2009). Further, 32 intragenic miRNAs significantly   correlated 
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  associated with high-risk MM. The findings of Zhou et al. (2010) 
clearly suggest that depletion of AGO2, involved in miRNA genesis 
and functionality, is associated with growth arrest and apoptosis 
in MM cells. Altered expression of AGO2 might lead to impaired 
miRNAs genesis thereby affecting their functions in MM patho-
genesis. In agreement, it was recently shown that altered expression 
of Dicer, but not Drosha, might be associated with progression 
and prognosis of MM. In particular, it was suggested that MGUS 
premalignant cases display higher levels of Dicer than do SMM 
and MM cases and are very similar to normal PCs (Sarasquete 
et al., 2010). Moreover, higher expression of Dicer was associated 
with improved progression-free survival in symptomatic MM cases. 
Whether upregulation of Dicer in MGUS and MM is associated 
with that of their host genes of which some are known genes 
  implicated in MM including miR-152-COPZ2, miR-335-MEST, 
and miR-342-3p-EVL (Ronchetti et al., 2008; Lionetti et al., 2009). 
Collectively, these data suggest that CN and frequent co-expression 
of intronic miRNAs with their respective host genes could be lead-
ing mechanisms to altered miRNAs expression in MM.
Since MM is characterized by very complex cytogenetic aberra-
tions that affects prognosis and molecular profiling (Sawyer, 2011), 
it is likely that these aberrations might affect miRNA expression as 
well. Indeed, recent studies have shown, for example, that upregula-
tion of miR-1 and miR-133a is correlated with t(14;16) MM cases 
suggesting that deregulation of miRNA expression could be associ-
ated with chromosomal aberrations (Gutierrez et al., 2010). Other 
examples are shown in Table 1.
Table 1 | miRNA genes deregulated in specific cytogenetic aberrations in multiple myeloma.
Cytogenetic Group  Deregulated miRNA  Chromosomal  microRNA target 
   location
t (4;14)a  Hsa-miR-133b  6p12.2 FSCN1
  Hsa-miR-135b  1q32.1 
  Hsa -miR-146a  5q34  IRAK1, Fas, Smad4, TBP , CCL8/MCP-2
  Hsa -miR-155  21q21.3  KPC1, IL -13Rα1, CYR61, SMAD1, SMAD2SMAD5, HIVEP2, 
      CEBPB, RUNX2, MYO10, PKIalpha, JARID2, AGTR1
  Hsa-miR-193a  17q11.2 
  Hsa-miR-196b  7p15.2 
  Hsa-miR-203  14q32.33  P63, SOCS-3
  Hsa-miR-215  1q41  DHFR, TS
  Hsa-miR-342  14q32.2 
  Hsa-miR-375  2q35  YAP , RASD1, PDK1, 14 3.3zeta
  Hsa-miR-650  22q11.22  NDRG2, ING4
t (11;14)a  Hsa-miR-95  4p16.1 SNX1 
  Hsa-miR-125a  19q13.41  PDPN, BAK1, KLF13, preproET1, ARID3B, HuR, ERBB2, ERBB3
  Hsa-miR-184  15q25.1 AKT2
  Hsa-miR-199a  19p13.2/1q24.3  CD44, mTOR, c-MET, HIF-1alpha
  Hsa-miR-215  1q41  DHFR, TS
  Hsa-miR-375  2q35  YAP , RASD1, PDK1, 14 3.3zeta
  Hsa-miR-650  22q11.22  NDRG2, ING4
t (14;16)b  Hsa-miR-1  20q13.33  TAGLN2, KLF4, c-Met
  Hsa-miR-99b  19q13.41 
  Hsa-miR-125a-5p  19q13.41  PDPN, BAK1, KLF13, preproET1, ARID3B, HuR, ERBB2, ERBB3
  Hsa-miR-133a  18q11.2/20q13.33 
  Hsa-miR-135b  1q32.1 
  Hsa-miR-196b  7p15.2 
  Hsa-miR-214  1q24.3 Pten
  Hsa-miR-375  2q35  YAP , RASD1, PDK1, 14 3.3zeta
  Hsa-miR-642  19q13.32 
Del 13q14c  Hsa-miR-15a-16 cluster  13q14.3  E2F , CCND1, WNT3A, BCL2
  Hsa-miR-181a/b  1q32.1/9q33.3  RASSF1A, TIMP3, NLK, Prox1, HOX-A11
  Hsa-miR-221  Xp11.3  P27 , Ets1, PUMA, p57 , TIMP3, Bmf, PTEN, Mdm2
  Hsa-miR-222  Xp11.3  P27 ,PUMA, p57 , TIMP3, PTEN
  Hsa-miR-382  14q32.31  SOD2, NPM1, PSPC1, HSPD1, ECH1
aGutierrez et al. (2010).
bLionetti et al. (2009), Gutierrez et al. (2010).
cRoccaro et al. (2009), Corthals et al. (2010).
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MM pathogenesis. Indeed, the functional role of miR-15a/16 in 
MM cells revealed their regulation of cell proliferation, survival, 
and cell cycle progression in vitro and in vivo (Roccaro et al., 2009). 
Recent studies from our laboratory have shown that the expression 
of the DLEU-2 gene, located at 13q14.3 and containing miR-15a/16 
clusters, is completely absent in MM cells as well as in normal PCs. 
Nevertheless, miR-15a and miR-16 are indeed downregulated. This 
might strongly suggest that the expression of these miRNAs could 
be driven from their related cluster at chromosome 3 (q25.33). 
Alternatively, an internal promoter unrelated to the host gene could 
drive their expression in PCs.
Although at the genetic level it is still considered an open ques-
tion, at the molecular level miR-15a/16 are shown to regulate cell 
cycle proteins including cyclinD1, cyclinD2, and CDC25A expres-
sion. Moreover, miR-15a/16 target BCL2 expression (Aqeilan et al., 
2010) and their overexpression in MM cells induces apoptosis as 
indicated by an increased percentage of sub-G1 population. MiR-
15a/16 were also shown to inhibit AKT3 and NFκB pathways in 
MM cells (Roccaro et al., 2009). Moreover, ectopic expression of 
miR-15a/16 displayed antiangiogenic activity through regulation 
of VEGF. Most recently, Gatt et al. further investigated the tumor 
suppressor role of miR-15a/16 in MM (Gatt et al. 2010). Using 
“sponge” lentiviral vectors directed toward the mature form of 
miR-15a/16, it was shown that inhibition of miR-16 enhanced 
proliferative and invasive ability of MMS1 cells in vitro. Further, 
depletion of miR-16 decreased animal survival in a xenograft 
model of MM through increasing tumor load and host angio-
genesis. Gene expression profiling of miR-16-depelted MM1S 
cells revealed a large number of miR-16 target genes including 
FGFR1, VEGFa, and MDM4. Importantly, miR-16 levels correlated 
with 13q14 deletion in MM samples and with those having larger 
blood vessels (Gatt et al. 2010). These observations clearly support 
the fact that a single miRNA, for example miR-16, can have far-
reaching effects on the overall function of the cell. Altogether, it is 
becoming obvious that miR-15a/16 are critical regulators of MM 
pathogenesis through targeting of multiple pathways implicated 
in clonal PCs and bone marrow neoangiogenesis.
MirnA functIonAl cross-tAlk wIth p53 In MultIple 
MyeloMA
The tumor suppressor p53 is frequently inactivated by mutations or 
deletions in cancer. p53 acts as a potent transcription factor and can 
be activated in response to diverse stresses, leading to induction of 
cell cycle arrest, apoptosis, or senescence (Xue et al., 2007; Junttila 
and Evan, 2009). Although regulation of the p53 pathway is not 
fully understood at the molecular level, it has been well established 
that activated p53 suppresses cancer progression, underscoring 
why cancer cells have developed multiple mechanisms to disable 
p53 function (Danovi et al., 2004; Ventura et al., 2007). In human 
tumors that retain wild-type (WT) p53 (Lane, 2001; Junttila and 
Evan, 2009), p53 can be antagonized by murine double minute 2 
(MDM2), a negative regulator of p53 that is overexpressed in many 
human tumors, offering a therapeutic strategy (Brown et al., 2009; 
Dickens et al., 2010). Indeed, it has been reported that inhibiting 
MDM2 expression can reactivate p53 in cancer cells, leading to 
their demise (Dickens et al., 2010; Saha et al., 2010a,b).
with impaired miRNA expression and function is still to be deter-
mined. These findings may shed light on the potential prognostic 
and therapeutic strategies in which regulators for both miRNA 
maturation and function, such as AGO2 and Dicer, might be used 
as prognostic tools and/or treatments of MM.
deregulAtIon of mirnAs regulAtes crItIcAl genes 
AssocIAted wIth MM
Deregulation of miRNAs was shown to be associated with target-
ing coding genes that are implicated in MM. For example, miR-
17∼92 cluster located at 13q31-32, a region frequently amplified in 
malignant B-cell lymphomas (He et al., 2005), and overexpressed 
in 65% of the B-cell lymphoma patients (Ota et al., 2004), has been 
shown to contribute to B-cell lymphoma by targeting PTEN, E2F1, 
and BIM. By overexpressing miR-17∼92 in lymphoid progenitor 
cells from mice that carry the MYC transgene, He et al. reported 
an accelerated lymphomagenesis by the cluster (He et al., 2005). 
A different group generated mice with high miR-17-92 lympho-
cytic expression and observed a higher rate of lymphoproliferative 
disorders, autoimmunity, and premature death in the transgenic 
mice (Xiao et al., 2008). Further, the work of Ventura et al. (2008) 
demonstrated that this cluster is essential for B-cell development 
and that its deficiency leads to increased levels of the pro-apoptotic 
protein BIM thereby inhibiting the transition of pro-B to pre-B 
stage. Therefore, it is likely that upregulation of the miR-17∼92 
cluster negatively regulates these critical tumor suppressor genes 
contributing to PCs transformation and MM progression.
On the other hand, the miR-106∼25 cluster together with miR-
32 were shown to target PCAF (Pichiorri et al., 2008), a p53 posi-
tive regulator (Schiltz and Nakatani, 2000; Linares et al., 2007). 
Downregulation of PCAF could keep p53 at low level via its his-
tone acetyltransferase function contributing to MM progression. 
Additionally, miR-106a/b, miR-17-5, and miR-20b were shown to 
target the CDKN1A1/p21 cell cycle regulator implicated in MM 
(Chen et al., 1999; Lavelle et al., 2001). Another central pathway 
that is deregulated in MM pathogenesis is the STAT-3/IL-6 pathway 
(Bommert et al., 2006). Targeting of this pathway by miR-19a/b 
was demonstrated in MM cells (Pichiorri et al., 2008). MiR-19a/b 
directly targets a negative regulator of IL-6, SOCS1, contributing 
to its frequent downregulation in MM cells. Importantly, xenograft 
studies using human MM cell lines treated with miR-19a/b and 
miR-181a/b antagonists (antimiRs) resulted in significant suppres-
sion of tumor growth in immunocompromised mice (Pichiorri 
et al., 2008).
MirnAs 15a/16-1 functIon As tuMor suppressors In MM
As mentioned above, miR-15a and miR-16-1 are located at 13q14.3, 
a region that is commonly deleted in CLL and MM among other 
malignancies (Aqeilan et al., 2010). Deletion of this region occurs 
in more than 50% of cases and is believed to take place at an early 
stage of the disease suggesting that it might be associated with 
MM pathogenesis (Fonseca et al., 2004). MiRNA expression pro-
filing of bone marrow derived CD138 +  MM cells versus their 
normal cellular counterparts identified an MM-specific miRNA 
signature characterized by significant downregulation of miR-
15a/16 (Roccaro et al., 2009; Corthals et al., 2010). Similar to CLL, 
it was hypothesized that minimal deletion in 13q14.3 containing 
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port the hypothesis that the transition from MGUS to MM could be 
favored by clonal selection of cells with the epigenetic inactivation 
not only of p53 but principally of its direct targets. This could 
be associated with a decreasing ability of p53 to down-modulate 
MDM2 expression thus tipping the regulatory balance in favor of 
MDM2 in MM cells. Whether methylation of the miR-194-2-192 
promoter in primary patients and in MGUS is responsible for this 
cluster inactivation is currently under investigation.
We and others also have shown that the upregulation of miR-25 
and miR-181a in MM cells of a specific set of miRNAs could negatively 
regulate the expression of the tumor suppressor gene p53 emphasiz-
ing the important cross-talk between p53 and aberrant microRNA 
expression in MM cells (Kumar et al., 2010; Pichiorri et al., 2010). 
Of note, monoallelic deletion of TP53 in MM, which often seems 
to occur without mutation on the other allele, is associated with an 
extremely poor prognosis (Chng et al., 2007). This supports the idea 
that a decrease in TP53 gene content is associated with tumor progres-
sion, which supports the hypothesis that a partial lack of expression 
of these miRNAs in MMs could create a p53 imbalance with direct 
biological consequences. The deletion of one copy of p53 by FISH 
has been uniformly found to be an adverse prognostic factor with 
all therapies used in the treatment of MM: alkylating agents, protea-
some inhibitors, and immune modulator-based therapies (Lode et al., 
2010). Due to the emerging role of epigenetic modifications in MM 
progression and the key role of p53 regulation by miRNAs it should 
be relevant to know if deacetylase inhibitors (DACi) could affect a 
set of miRNA expression in MM cells able to affect p53 re-expression 
making the cells more sensitive to further therapies.
conclusIons And future perspectIves
Genetic alterations in MM have been identified and were shown 
to be associated with different biologic features and heterogeneity 
in clinical outcome. Recent research work highlights the   possible 
 contribution of a new class of non-coding genes, miRNA (Figure 1). 
TP53 mutation is rarely detected at diagnosis in many 
  hematological cancers including MM, CLL, acute myeloid leuke-
mia, and Hodgkin’s disease. Thus, numerous reports have shown 
that therapeutic induction of p53 might be particularly suitable for 
the treatment of hematological malignancies (Saha et al., 2010b) 
including MM (Kuehl and Bergsagel, 2002; Fonseca et al., 2009). 
Mutations of p53 are rare in untreated MM and the tumors appear 
to have intact, if perhaps suppressed, p53 function, suggesting that 
therapeutic modulation of the p53/MDM2 pathway holds promise 
to help the majority of patients. Several reports (Quesnel et al., 
1994; Teoh et al., 1997) and our data suggest that MDM2 overex-
pression in MMs, not its gene amplification (Quesnel et al., 1994), 
could be responsible for p53 inactivation in cells retaining func-
tional p53 pathways. This supports the idea that induction of p53 in 
this setting might be a suitable treatment for MM. Interestingly, in 
MM cells, expression of p53 protein levels can be rescued by antago-
nizing MDM2. Several reports have focused on the p53-mediated 
apoptotic pathway, upon endogenous p53 protein re-expression 
by the small-molecule MDM2 antagonists (Nutlins) and target 
genes which may be involved in p53-dependent apoptosis in MM 
cells which have been identified (Stuhmer and Bargou, 2006). We 
recently showed that alteration in miRNA expression during the 
progression from MGUS to newly diagnosed MM could partially 
be responsible for p53 inactivation in MM patients (Pichiorri 
et al., 2010). We found that, among others, miR-192, 194, and 215, 
which are downregulated in a subset of newly diagnosed MMs, can 
be transcriptionally activated by p53 and then modulate MDM2 
expression (Table 2). Furthermore, ectopic re-expression of these 
miRNAs in MM cells increases the therapeutic action of MDM2 
inhibitors in vitro and in vivo by enhancing their p53-activating 
effects. In addition, miR-192 and 215 target the IGF pathway, pre-
venting enhanced migration of PCs into bone marrow.
In seeking an explanation for the lack of expression of these 
miRNAs in MM, we have noted that the genes for these miRNAs 
are located in chromosomal regions in MM that are normally 
characterized by chromosome gain and translocations rather 
than deletions (Fonseca et al., 2009). This led us to hypothesize 
that other mechanisms are responsible for the observed down-
regulation of these miRNAs. Indeed, it turns out that epigenetic 
cross-talk between methylation and histone acetylation (Vaissiere 
et al., 2008; Walker et al., 2011) in the promoter of the miR-194-2-
Table 2 | miRNAs deregulation associated with p53 expression in 
multiple myeloma.
p53 associated  Chromosomal location  References 
miRNAs
miR-34a  1p36.22  Chim et al. (2010)
miR-192  11q13.1  Pichiorri et al. (2010)
miR-215  11q13.1/1q41  Pichiorri et al. (2010)
miR-22  17p13.3  Lionetti et al. (2009)
miR-194  1q41  Pichiorri et al. (2010)
miR-125b  11q24.1/21q21.1  Kumar et al. (2010)
miR-25  7q22.1  Kumar et al. (2010)
miR-30d  8q24.22  Kumar et al. (2010)
miR-181-a/b  1q32.1/9q33.3  Pichiorri et al. (2008)
FiGuRe 1 | Schematic drawing showing the multistep molecular process 
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